Breye Therapeutics Raises €67.5M Series A for Oral Retinal-Disease Therapy
Breye Therapeutics raised an oversubscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into Phase II.
biotech — Venture Capital Articles & Research
Explore our latest articles on biotech — covering venture capital deals, fund activity, startup fundraising strategy, and investor research relevant to this topic.
Whether you're a founder building an investor target list, an analyst tracking deal flow, or an operator researching market trends, the articles below provide practical, up-to-date venture capital intelligence.
Why This Topic Matters in VC
- Deal flow signal: Funding activity and investor conviction in biotech
- Fundraising context: Which investors are active and what traction they expect
- Market timing: Sector momentum, valuation benchmarks, and competitive dynamics
Browse all biotech articles below, or use our investor list to research active investors by stage and sector.
Related Articles (24 articles)
-
-
AvenCell's $47M Financing Is Mostly Royalty Capital, Not a $47M Series C
Ligand committed up to $47 million to AvenCell Therapeutics, but only up to $6 million is Series C equity; up to $41 million is milestone-based royalty financing.
-
Pilgrim Raises $25M Seed at a Reported $150M Valuation
Biosecurity startup Pilgrim raised $25 million at a reported $150 million valuation to develop systems for detecting airborne biological threats.
-
Penelope Health Gets $100M Funding Commitment for Real-Time Policy Intelligence
Penelope Health announced a $100 million funding commitment from Thoreau and other investors to expand real-time payer and provider policy intelligence.
-
Encoded Therapeutics Raises $275M Series F to Take Its Dravet Gene Therapy Through Pivotal Development
GV and an unnamed healthcare fund co-led Encoded Therapeutics' $275 million Series F, financing pivotal ETX101 studies, internal GMP scale-up, and a 2027 IND target for ETX301.
-
Moonwalk Biosciences Raises $70M Series B for Adipose-Targeted RNAi
Moonwalk Biosciences raised an oversubscribed $70 million Series B to advance adipose-targeted RNAi medicines for obesity and cardiometabolic disease.